FDA approves St. Jude’s safety-enhanced devices

Candace Stuart | June 14, 2013 | Cardiovascular Business | Heart Rhythm

The FDA approved next-generation implantable defibrillators that offer new safety and performance features.

Minneapolis-based St. Jude Medical announced its Ellipse and SJM Assura family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) include an algorithm that ensures therapy is delivered in the event of an electrical short and a low-friction coating on the device that can reduce friction between the device and leads.

A past analysis of some Durata leads had found abrasions and abrasions that resulted in high-voltage failures. St. Jude recalled its Riata and Riata ST silicone leads in late 2011 due to insulation failures.

The Ellipse and Assura portfolio of ICDs and CRT-Ds received CE mark in Europe in May.

Candace Stuart, Contributor

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

FDA approves St. Jude’s safety-enhanced devices

Related Content

Around the web